<DOC>
	<DOCNO>NCT00662038</DOCNO>
	<brief_summary>This open-label , multi-center , extension study patient IPF complete qualify InterMune clinical trial pirfenidone . The purpose study obtain additional safety data pirfenidone 2403 mg/day patient IPF complete qualify InterMune clinical trial pirfenidone .</brief_summary>
	<brief_title>Open-Label Study Long Term Safety Pirfenidone Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description>This open-label , multi-center , extension study patient IPF complete qualify InterMune clinical trial pirfenidone . Eligible patient must complete final visit qualify study , permanently discontinue study drug qualify study , meet eligibility criterion note protocol . Since data qualify study may remain blinded patient enrollment PIPF-012 , patient treat take placebo qualify study . At start PIPF-012 participation , patient escalate dose pirfenidone . The duration treatment patient vary continue pirfenidone commercially otherwise available his/her geographic region study terminate sponsor reason outline protocol .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Completes qualify clinical study final visit In opinion principal investigator ( PI ) , generally compliant study requirement qualify study , must consider eligible enroll PIPF012 InterMune medical monitor Is able provide inform consent comply requirement study Is pregnant lactating Has know hypersensitivity component study drug Starts participation another interventional clinical trial end participation qualify InterMune clinical trial entry PIPF012 Receives concomitant and/or exclude medication define protocol Permanently discontinues study drug qualify study reason study completion</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>idiopathic</keyword>
	<keyword>pulmonary</keyword>
	<keyword>fibrosis</keyword>
</DOC>